Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials

Using amyloid PET imaging as a single primary surrogate efficacy measure in Alzheimer’s disease immunotherapy trials, as happened when the FDA granted accelerated approval of aducanumab, is unjustified. In vivo evidence indicates that PET quantification of amyloid deposition is distorted and misrepr...

Descripción completa

Detalles Bibliográficos
Autores principales: Høilund-Carlsen, Poul F., Revheim, Mona-Elisabeth, Alavi, Abass, Satyamurthy, Nagichettiar, Barrio, Jorge R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789473/
https://www.ncbi.nlm.nih.gov/pubmed/36278356
http://dx.doi.org/10.3233/JAD-220841

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789473/
https://www.ncbi.nlm.nih.gov/pubmed/36278356
http://dx.doi.org/10.3233/JAD-220841

Ejemplares similares